Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab + Cetuximab in Solid Tumors and CRC
NCT02953782Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2016
- Primary completion
- Feb 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of magrolimab in solid tumor and colorectal cancer (CRC) (8 cohorts), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants With Dose Limiting Toxicities at Day 28, Percentage of Participants Experiencing Treatment-Emergent Adverse Events up to 15.3 months and 1 more. Started Nov 2016; status: completed.
02
Drugs
magrolimab
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02953782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953782.